Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN1611 + Cetuximab in PIK3CA-mutated mCRC
NCT04495621Phase 2Completed
- Sponsor
- Menarini Group
- Start
- Jul 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of izorlisib in metastatic colorectal cancer (mCRC), sponsored by Menarini Group. Started Jul 2020; status: completed.
02
Drugs
izorlisib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04495621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495621.